MenopauseNCT07242391
Menopausal Hormone Therapy And Left Ventricular Function
An observational study of Menopause and Left Ventricular Dysfunction, run by Mayo Clinic at 1 site in United States.
Trial summary
The purpose of this study is to compare left ventricular stroke volume and heart rate responses to bursts of SNA between PMF using, and not using, MHT. Read more about this study
- Who is it for?
- Ages 45 to 60 years, women only
- Conditions the study is for
- Menopause, Left Ventricular Dysfunction
- What is being tested?
- Menopausal Hormone Therapy
- Type of treatment
- Pill or oral medicine
- How many people
- 50 participants
- Where
- 1 siteUnited States
- Study dates
- 26 Aug 2026to Dec 2027
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 45 to 60 years
- Women only
- Adult
Study population: Study participants will be recruited from various Mayo Clinic departments/clinics located at Rochester and surrounding communities.
Who may be able to join
- >45-60< years of age
Who cannot join
- Male sex
- Females between STRAW+10 stages -5 and 0
- PMF in STRAW+10 stage +2
- PMF using oral hormone therapy
- Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy)
- Heart disease such as hypertropic cardiomyopathy, congenital abnormalities, chronic heart failure, valve disease, and a history of myocardial infarction
Show all 18Show fewer
- Medications that impact the central nervous system including selective serotonin reuptake inhibitors, anxiolytics, sedatives, anticholinergic agents, dopamine, amphetamines, or wake-promoting agents (e.g., modafinil). Other medications will be evaluated on an individual basis by the PI.
- Cardiovascular medications is also an exclusion criterion which includes those acting on the renin-angiotensin-aldosterone axis, adrenergic receptor antagonists, diuretics, nitrates, and calcium channel antagonists. Other medications will be evaluated on an individual basis by the PI.
- Pregnancy
- COPD
- Diabetes
- CKD
- Raynaud's phenomenon
- Sleep disorders
- Shift workers
- BMI ≥40.0kg/m2
- Use of nicotine-containing products within the two years preceding study visits
- Active cancer treatment
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
Mayo Clinic in Rochester
Rochester, Minnesota, 55905
Joshua Bock, PhD, (507) 422-0768, bock.joshua@mayo.edu
Joshua Bock, PhD
About this study
Official title: Menopausal Hormone Therapy And Neural Control Of Left Ventricular Function
The purpose of this study is to compare left ventricular stroke volume and heart rate responses to bursts of SNA between PMF using, and not using, MHT.
- Conditions
- Menopause, Left Ventricular Dysfunction
- Being tested
- Menopausal Hormone Therapy
- Medical subject headings
- Ventricular Dysfunction, Left
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Menopausal Hormone TherapyDrug
Taken in accordance with standard clinical practice, administered for a minimum duration of eight weeks.
| Study group | Role | What they receive |
|---|---|---|
| Post-menopausal females using menopausal hormone therapy | Post menopausal females taking a clinically prescribed menopausal hormone therapy (i.e. pill, patch, etc.) Receives: Drug: Menopausal Hormone Therapy | |
| Post-menopausal females not using menopausal hormone therapy | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Left ventricular stroke volume
Left ventricular stroke volume is the amount of blood pumped from the left ventricle per heartbeat (mL)
Measured: Baseline
Secondary outcomes (1)
Ventriculo-Arterial (VA) coupling
Ventriculo-Arterial (VA) coupling will be measured as the ratio of end-systolic elastance (Ees) to arterial elastance (Ea).
Measured: Baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted21 Nov 2025
- Study start26 Aug 2026
- Primary completionDec 2027 (estimated)
- Study completionDec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for MenopauseStudies of the same condition, open and under way.
- More trials run by Mayo ClinicThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Other
- Time perspective
- Cross-sectional
- Enrolment
- 50 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Mayo Clinic
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Joshua M. Bock, Mayo Clinic
- Investigators
- Joshua Bock, Ph.D., Principal investigator, Mayo Clinic
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07242391
- Sponsor's protocol ID
- 25-006388
- Status last verified
- Aug 2026
- First submitted
- 17 Nov 2025
- Last updated
- 27 Aug 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Aug 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Menopausal Hormone Therapy And Neural Control Of Left Ventricular Function
- ClinicalTrials.gov ID
- NCT07242391
- Acronym / sponsor ID
- 25-006388
- Conditions
- Menopause, Left Ventricular Dysfunction
- Study type
- Observational
- Recruitment status
- Recruiting
- Enrolment
- 50 participants (estimated)
- Lead sponsor
- Mayo ClinicUniversity, hospital or other
- Study start
- 26 Aug 2026 (actual)
- Primary completion
- Dec 2027 (estimated)
- Study completion
- Dec 2027 (estimated)
- First posted
- 21 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare left ventricular stroke volume and heart rate responses to bursts of SNA between PMF using, and not using, MHT.
Study design
- Observational model
- Other
- Time perspective
- Cross-sectional
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Post-menopausal females using menopausal hormone therapy | – | Drug: Menopausal Hormone TherapyPost menopausal females taking a clinically prescribed menopausal hormone therapy (i.e. pill, patch, etc.) |
| Post-menopausal females not using menopausal hormone therapy | – | – |
Who may qualify
- Ages
- 45 to 60 years
- Sex
- Female only
- Age groups
- Adult
- Study population
- Study participants will be recruited from various Mayo Clinic departments/clinics located at Rochester and surrounding communities.
Key inclusion criteria (1 listed)
- >45-60< years of age
Key exclusion criteria (18 listed)
- Male sex
- Females between STRAW+10 stages -5 and 0
- PMF in STRAW+10 stage +2
- PMF using oral hormone therapy
- Females who entered menopause due to a surgical procedure or in response to pharmacotherapy (e.g., gonadotrophin releasing hormone agonists or chemotherapy)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Menopausal Hormone TherapyTaken in accordance with standard clinical practice, administered for a minimum duration of eight weeks. | Drug | Post-menopausal females using menopausal hormone therapy |
Primary outcome
Left ventricular stroke volume
Time frame: Baseline
Left ventricular stroke volume is the amount of blood pumped from the left ventricle per heartbeat (mL)
1 secondary outcome
Ventriculo-Arterial (VA) coupling
Time frame: Baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Aug 2026.
- Individual participant dataSharing planned: No
Related trials for Menopause
RecruitingObservational study
Health, Imaging, and Cognition Across the Menopausal Transition
Menopause
RecruitingObservational study
Biorepository in Participants Who Undergo OTC for Gonadotoxic Therapy
Acute Ovarian Failure, Infertility
Not yet recruiting
Waning Moon: A Whole Person Health Intervention Designed by and for Urban Menopausal American Indian/Alaska Native Women
Menopause, Vasomotor Symptoms (VMS)
Enrolling by invitation
Transcutaneous Auricular Neurostimulation (tAN) for Premenstrual Dysphoric Disorder (PMDD) and Perimenopause
Perimenopause, PMDD
RecruitingObservational study
QoLIDia: Quality of Life in Cancer Patients With Diabetes During Immunotherapy
Cancer, Type 2 Diabetes
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Joshua Bock, Ph.D. principal investigator
Mayo Clinic
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Menopause and Left Ventricular Dysfunction, run by Mayo Clinic at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 18 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 27 Aug 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Joshua Bock, Ph.D. (507-422-0768, bock.joshua@mayo.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Left ventricular stroke volume (time frame: Baseline). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Aug 2026.